Rinatabart Sesutecan

August 6, 2026 Copenhagen, Denmark; Interim Report for the Six Months Ended June 30, 2026 Highlights Genmab announced positive Phase 3 results for epcoritamab plus lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), demonstrating statistically significant improvement in progression-free survival Genmab revenue increased 25% compared to the first six months of 2025, to $2,051 million Genmab 2026 financial guidance updated “The second quarter of 2026 delivered clinical progress for our late-stage portfolio. Epcoritamab continued to demonstrate its potential as a core therapy across the spectrum of B-cell malignancies, with strong data across multiple treatment settings and patient populations. At the same time, new data further support the development of Rina-S® (rinatabart sesutecan) in combination in advanced ovarian cancer. Together, these results reflect our continued commitment to delivering meaningful advances for patients,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. Financial Performance First Half of 2026 Revenue was $2,051 million for the first six months of 2026 compared to $1,640 million for the first six months of 2025. The increase of $411 million, or 25%, was primarily driven by higher DARZALEX® and Kesimpta® royalties and higher EPKINLY® net product sales. Royalty revenue was $1,708 million in the first six months of 2026 compared to $1,378 million in the first six months of 2025, an increase of $330 million, or 24%. The increase in royalties was driven by higher net sales of DARZALEX and Kesimpta. Net sales of DARZALEX by J&J were $8,171 million in the first six months of 2026 compared to $6,776 million in the first six months of 2025, an increase of $1,395 million or 21%. Global net sales of EPKINLY/TEPKINLY® were $312 million in the first six months of 2026 compared to $211 million in the first six months of 2025, an increase of $101 million or 48%. Cost of product sales were $149 million for the first six months of 2026 compared to $99 million for the first six months of 2025. The increase of $50 million, or 51%, was primarily driven by the profit-sharing amounts payable to AbbVie related to EPKINLY sales. Adjusted operating expenses, excluding Acquisition and integration related charges, were $1,270 million for the first six months of 2026 compared to $993 million for the first six months of 2025. The increase of $277 million, or 28%, was primarily driven by investment in our product pipeline, including the advancement of Rina-S and petosemtamab, and our global commercialization capabilities in preparation for their anticipated launches. Acquisition and integration related charges related to the integration of Merus were $77 million in the first six months of 2026. Amortization of acquired intangible assets was $24 million for the first six months of 2026 compared to $6 million for the first six months of 2025. The increase of $18 million, was primarily driven by the amortization of the Merus technology platform. Operating profit was $555 million in the first six months of 2026 compared to $548 million in the first six months of 2025. Adjusted operating profit, which excludes Acquisition and integration related charges and Amortization of acquired intangible assets, was $656 million in the first six months of 2026 compared to $554 million in the first six months of 2025. Outlook Genmab is updating its revenue, adjusted operating expenses and adjusted operating profit guidance for 2026. The improved guidance is driven by higher total royalty revenues from DARZALEX and net sales of EPKINLY. 2026 FULL YEAR OUTLOOK 1 Net product sales/Collaboration revenue consists of EPKINLY net product sales in the U.S. and Japan, and Tivdak® ex-U.S. net product sales plus Genmab's share of U.S. gross profits. 2 Adjusted operating expenses and operating profit exclude 2026 charges related to: 1) acquisition and integration-related charges of $90 million and 2) amortization of intangible assets acquired through acquisitions of $47 million. 3 Adjusted operating expenses and operating profit exclude 2026 charges related to: 1) acquisition and integration-related charges of $65 million and 2) amortization of intangible assets acquired through acquisitions of $45 million. Non-IFRS Financial Measures Our Adjusted operating expenses and Adjusted operating profit excludes acquisition and integration related charges and amortization of acquired intangible assets. These charges were recognized in prior periods and will likely reoccur in future periods. These items are excluded from operating expenses and operating profit because the Company believes they neither relate to the ordinary course of the Company's business nor reflect the Company's underlying business performance. Non-IFRS information is intended to portray the results of our baseline performance, supplement or enhance management's, analysts' and investors’ overall understanding of our underlying financial performance and facilitate comparisons among current, past and future periods. This information is not intended to be considered in isolation or as a substitute for the related financial measures prepared in accordance with IFRS and may not be the same as or comparable to similarly titled measures presented by other companies due to possible differences in method and in the items being adjusted. We encourage investors to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure. Conference Call Genmab will hold a conference call to discuss the results for the first six months of 2026 today, Thursday, August 6, at 6:00 pm CEST, 5:00 pm BST or 12:00 pm EDT. To join the call please use the below registration link. Registered participants will receive an email with a link to access dial-in information as well as a unique personal PIN: https://register-conf.media-server.com/register/BId9cf2ff8aa3c489ca2ad2007d64a1964. A live and archived webcast of the call and relevant slides will be available at www.genmab.com/investor-relations. Contact Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs T: +1 609 524 0065; E: mmp@genmab.com Andrew Carlsen, Vice President, Head of Investor Relations T: +45 3377 9558; E: acn@genmab.com The Interim Report contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in the Interim Report nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law. Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®; HexElect®; KYSO®, RAINFOL™, ProfoundBio™ and Rina-S® are trademarks of ProfoundBio, U.S., Co. and Genmab (Suzhou) Co., Ltd. Tivdak® is a trademark of Seagen Inc.; EPCORE®, EPKINLY®, TEPKINLY® and their designs are trademarks of AbbVie Biotechnology Ltd.; Biclonics® and BIZENGRI® are registered trademarks of Merus N.V. Kesimpta® and Sensoready® are trademarks of Novartis AG or its affiliates; DARZALEX®, DARZALEX FASPRO®, RYBREVANT®, RYBREVANT FASPRO™,TECVAYLI® and TALVEY® are trademarks of Johnson & Johnson; TEPEZZA® is a trademark of Horizon Therapeutics Ireland DAC. Download the full Interim Report for the First Half of 2026 on attachment or at www.genmab.com/investor-relations CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122 Genmab A/S Carl Jacobsens Vej 30 2500 Valby Denmark Attachment 060826_CA34_Genmab Interim Report H1 2026

实体瘤是一种在器官或组织中形成的固体肿块，与血液系统中的肿瘤（如白血病）不同，它不会在血液中流动。实体瘤可以发生在身体的任何部位，例如脑、肺、肝、胰腺等。根据发生的部位不同，实体瘤可分为头颈部肿瘤、胸部肿瘤、消化系统肿瘤、泌尿生殖系统肿瘤、骨肿瘤、中枢神经系统肿瘤、软组织肿瘤、皮肤及附件肿瘤等。 01 试验标题 一项研究Rina-S用于局部晚期和/或转移性实体瘤患者的I/II期 研究 试验分期：Ⅰ/Ⅱ期 登 记 号：CTR20230813 申 办 方：普方生物制药（苏州）有限公司 02 适 应 症 1-3线治疗失败子宫内膜癌肉瘤、铂耐药卵巢癌 03 研究用药 实 验 组：Rina-S单药（注射用PRO1184） 药物介绍：叶酸受体α（FRα）靶点ADC药物 04 入选重点 ✅铂耐药卵巢癌：1-3线未接受过索米妥昔单抗单抗治疗的铂耐药卵巢癌患者；✅高级别上皮性卵巢癌、原发性腹膜癌或输卵管癌，包括浆液性、子宫内膜样和透明细胞癌，不包括粘液性、低级别和具有肉瘤样或神经内分泌特征的癌症。❌既往接受过拓扑异构酶I抑制剂抗体-药物偶联物治疗 05 入选标准 1.患者必须患有经组织学或细胞学证实的转移性或不可切除的恶性实体瘤。患者既往必须接受过所有已知能带来临床获益的疗法 ：G部分 患者必须患有经组织学或细胞学证实的子宫内膜癌○队列B5：复发性或进展性子宫内膜癌肉瘤o患者必须既往接受过1～3线治疗，并且在最近一线治疗期间或之后出现影像学进展。o患者必须既往接受过含铂化疗和PD-(L)1抑制剂治疗。完成含铂化疗后＞12个月出现疾病进展的患者必须针对复发性疾病追加1次含铂化疗，除非患者不适合继续接受含铂化疗，在这种情况下，必须记录不适合的原因。注：如果在复发阶段给予免疫治疗，则无论与既往含铂化疗的治疗间隔多长，均无需再次使用铂类药物。在这种情况下，必须记录不适合含铂化疗的原因。o单独激素治疗（即，无化疗）将不被计为单独的治疗线。○队列B6：宫颈癌患者必须经组织学确诊为宫颈鳞状细胞癌、腺鳞癌或腺癌复发性或转移性宫颈癌，既往接受含铂双药化疗±贝伐珠单抗（如符合贝伐珠单抗治疗条件）联合抗PD-1/抗PD-L1治疗期间或之后出现疾病进展既往接受过≤2种针对复发性和/或转移性宫颈癌的系统性治疗方案。ECOG体能状态评分为0或1提供肿瘤组织（首选最新样本），来源于既往未接受过放疗的肿瘤病灶的粗针穿刺活检或切除活检；J部分：单药治疗未接受过MIRV治疗的PROC队列患者必须患有高级别上皮性卵巢癌、原发性腹膜癌或输卵管癌，包括浆液性、子宫内膜样和透明细胞癌，不包括粘液性、低级别和具有肉瘤样或神经内分泌特征的癌症。o患者必须既往接受过1～3线治疗：仅接受过1线既往含铂治疗的患者必须接受过至少4个周期的铂类药物治疗，并且必须达到缓解（CR或PR）或在含铂治疗开始时有不可测量的病灶，然后在铂类药物末次给药日期后＞91天至≤183天出现疾病进展接受过2或3线含铂治疗的患者必须在铂类药物末次给药当天或之后183天内出现疾病进展注：应从铂类药物末次给药的日期至影像学检查显示进展的日期计算进展o已知或疑似存在有害胚系或体细胞BRCA突变（由经CLIA认证的实验室通过经FDA批准的检测方法确定；或当地批准的等效方法确定）且含铂化疗后达到完全或部分缓解的患者必须接受多聚ADP-核糖聚合酶（PARP）抑制剂治疗作为维持治疗o在治疗期间无疾病进展的情况下，既往诱导+维持治疗被视为1线治疗，即使部分治疗方案（诱导或维持）中断和/或在以后某个日期恢复。o仅因毒性或患者偏好（而非疾病进展）导致的方案转换/变更不视为单独的治疗线患者必须基于FDA/NMPA批准的Ventana FOLR1 RxDx检测确认FRα阳性表达/水平（≥75%的肿瘤细胞呈中等和/或强膜染色）。该检测可在本地进行，如果无法获得本地结果，则需在入组前对样本进行中心检测，以评估FRα表达/水平状态。基线时根据实体瘤疗效评价标准（RECIST）第1.1版评估具有可测量病灶。2.所有患者均应同意提供一份治疗前的肿瘤样本（存档或新鲜活检样本）。3.年龄≥18岁。4.美国东部肿瘤协作组（ECOG）体能状态评分为0分或1分。5.基线时根据实体瘤疗效评价标准（RECIST）第1.1版评估具有可测量病灶。6.患者在收集基线实验室检查数据前2周内不得接受针对血小板、中性粒细胞或血红蛋白降低的支持性治疗。7.患者必须提供书面知情同意。 06 排除标准 （1）患有无法控制的糖尿病，定义为Hgb A1c≥8%或7%＜Hgb A1c＜8%，伴有相关糖尿病症状（多尿或烦渴），无其他原因。（2）在Rina-S首次给药前6个月内发生脑血管事件（卒中或短暂性脑缺血发作）、不稳定型心绞痛、心肌梗死、需要药物治疗的严重心律失常（不包括心室率受控的无症状房颤）或与纽约心脏病协会心功能分级III级至IV级症状一致的充血性心力衰竭。（3）在过去2年内既往患有需要类固醇治疗的（非感染性）间质性肺疾病（ILD）/肺部炎症，当前患有ILD/肺部炎症，或在筛选时影像学检查无法排除疑似ILD/肺部炎症。（4）若既往接受过抗肿瘤治疗，则在研究药物首次给药前需有2周（小分子药物）或4周（抗体疗法）的洗脱期。如果在接受抗体疗法期间，基础疾病发生恶化，则可以接受在研究药物首次给药前仅有2周的洗脱期。（5）既往接受过拓扑异构酶I抑制剂抗体-药物偶联物治疗（6）在过去3个月内因胃肠梗阻住院或出现临床症状，或在筛选时有胃肠梗阻的影像学证据。入组目前需要肠外营养的患者必须与研究医学监查员进行讨论，以确定其入组资格。（7）进入研究前4周内，存在需要治疗性穿刺术/胸腔穿刺的具有临床意义的腹水/胸腔积液。不得入组留置导管冲洗/引流的患者。（8）研究药物首次给药前12周内接受过超过25%骨髓的放射治疗或宽野放疗。（9）当前存在心包积液或有恶性心包积液病史的患者。J部分关键排除标准（1）患有无法控制的糖尿病，定义为Hgb A1c≥8%或7%＜Hgb A1c＜8%，伴有相关糖尿病症状（多尿或烦渴），无其他原因。（2）在Rina-S首次给药前6个月内发生脑血管事件（卒中或短暂性脑缺血发作）、不稳定型心绞痛、心肌梗死、需要药物治疗的严重心律失常（不包括心室率受控的无症状房颤）或与纽约心脏病协会心功能分级III级至IV级症状一致的充血性心力衰竭。（3）在过去2年内既往患有需要类固醇治疗的（非感染性）间质性肺疾病（ILD）/肺部炎症，当前患有ILD/肺部炎症，或在筛选时影像学检查无法排除疑似ILD/肺部炎症。（4）若既往接受过抗肿瘤治疗，则在研究药物首次给药前需有2周（小分子药物）或4周（抗体疗法）的洗脱期。如果在接受抗体疗法期间，基础疾病发生恶化，则可以接受在研究药物首次给药前仅有2周的洗脱期。（5）既往接受过MIRV或其他靶向FRα的抗体偶联药物治疗。（6）既往接受过拓扑异构酶I抑制剂抗体偶联药物治疗。（7）在过去3个月内因胃肠梗阻住院或出现临床症状，或在筛选时有胃肠梗阻的影像学证据。入组目前需要肠外营养的患者必须与研究医学监查员进行讨论，以确定其入组资格。（8）进入研究前4周内，存在需要治疗性穿刺术/胸腔穿刺的具有临床意义的腹水/胸腔积液。不得入组留置导管冲洗/引流的患者。（9）研究药物首次给药前12周内接受过超过25%骨髓的放射治疗或宽野放疗。（10）当前存在心包积液或有恶性心包积液病史的患者。1.患者在研究药物首次给药前3年内有另一种恶性肿瘤病史，或有证据表明既往诊断的恶性肿瘤存在残留病灶。2.已知患有活动性中枢神经系统转移或癌性脑膜炎。3.在Rina-S首次给药前2周内存在≥3级（根据NCI CTCAE第5.0版确认）且无法控制的病毒、细菌或真菌感染。4.患有无法控制的糖尿病。5.乙型肝炎表面抗原表达检测阳性。患有活动性丙型肝炎。6.人类免疫缺陷病毒（HIV）呈阳性。7.在Rina-S首次给药前6个月内发生脑血管事件（卒中或短暂性脑缺血发作）、不稳定型心绞痛、心肌梗死、需要药物治疗的严重心律失常（不包括心室率受控的无症状心房纤颤）或与纽约心脏病协会心功能分级III级至IV级症状一致的充血性心力衰竭。8.在过去2年内既往患有需要类固醇治疗的（非感染性）间质性肺疾病（ILD）/肺炎，当前患有ILD/肺炎，或在筛选时影像学检查无法排除疑似ILD/肺炎。9.若既往接受过抗肿瘤治疗，则在研究药物首次给药前需有2周（小分子药物）或4周（抗体疗法）的洗脱期。10.仅在剂量递增阶段：在研究药物给药前14天内使用过强效细胞色素P450 3A（CYP3A）抑制剂。11.在Rina-S首次给药前2周，仍有未完成的放疗或重大手术。12.具有生育能力的女性患者。13.具有生育能力的男性患者。14.当前或过去2年内患有具有临床意义的自身免疫性疾病或免疫缺陷，包括目前需要使用全身性免疫抑制剂治疗，即＞10 mg/天泼尼松当量（允许进行局部免疫抑制剂治疗，如吸入或外用皮质类固醇）。15.已知对Rina-S药物制剂中的任何辅料存在超敏反应。16.预期寿命＜12周。17.基线QTcF＞480 ms的患者。18.既往接受过拓扑异构酶I抑制剂抗体-药物偶联物治疗。19.患者在过去3个月内因胃肠梗阻住院或出现临床症状，或在筛选时有胃肠梗阻的影像学证据。20.需要定期接受穿刺术（大约每4周一次以上）对症治疗腹水的患者。21.存在研究者认为可能会影响患者接受或耐受计划治疗和随访的其他严重基础病症。22.进入研究前4周内，无需要治疗性穿刺术/胸腔穿刺的具有临床意义的腹水/胸腔积液。不得入组留置导管冲洗/引流的患者。23.研究药物首次给药前12周内接受过超过25%骨髓的放射治疗或宽野放疗。24.当前存在心包积液或有恶性心包积液病史的患者。 07 患者权益 1.研究期间相关检查免费 2.研究药物免费使用 3.专家定期随访及相关检查 4.权威的医疗专家对疾病的指导 5.一定的交通补助 08 研究中心 北京、重庆、福州、广州、郑州、武汉、长沙、长春、南昌、沈阳、太原、上海、天津 09 报名资料 1.最近一次入院记录 2.最近一次出院记录 3.病理报告、免疫组化、基因检测报告 4.最后两次CT报告 5.最近一次血常规、血生化、乙肝五项检查报告（1个月内） 【医研新招募】目前有肺癌、肝癌、肾癌、胃癌、肠癌、胰腺癌、妇瘤、泌尿肿瘤、血液肿瘤......等几乎涵盖所有癌种的临床试验正在招募患者！ 注：此项目为临床试验项目，具体开展时间、补助等详情，请以研究中心通知和知情同意书为准，更多项目请关注“医研新招募“公众号。